title: A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2012May 19-22, 2012 • San Diego, CaliforniaSpecial Reporting on:• Novel Infliximab and Antibody-to-lnfliximab Assays Are Predictive of Disease Activity in Patients with Crohn's Disease• Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated with Infliximab Maintenance Therapy• Putting It Together: Drug Levels and Disease Activity to Tailor Therapy• Infliximab Concentration and Clinical Outcome in Patients with Ulcerative ColitisPLUS Meeting Abstract Summaries With Expert Commentary by: William J. Sandborn, MDChief of the Division of GastroenterologyDirector of the UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.